The latest price target for Iovance Biotherapeutics (NASDAQ:IOVA) was reported by Baird on February 28, 2025. The analyst firm set a price target for $20.00 expecting IOVA to rise to within 12 months (a possible 375.06% upside). 17 analyst firms have reported ratings in the last year.

The latest analyst rating for Iovance Biotherapeutics (NASDAQ:IOVA) was provided by Baird, and Iovance Biotherapeutics maintained their outperform rating.

The last upgrade for Iovance Biotherapeutics Inc happened on May 30, 2023 when Wells Fargo raised their price target to $17. Wells Fargo previously had an equal-weight for Iovance Biotherapeutics Inc.

The last downgrade for Iovance Biotherapeutics Inc happened on July 29, 2024 when Piper Sandler changed their price target from $19 to $10 for Iovance Biotherapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Iovance Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Iovance Biotherapeutics was filed on February 28, 2025 so you should expect the next rating to be made available sometime around February 28, 2026.

While ratings are subjective and will change, the latest Iovance Biotherapeutics (IOVA) rating was a maintained with a price target of $24.00 to $20.00. The current price Iovance Biotherapeutics (IOVA) is trading at is $4.21, which is out of the analyst’s predicted range.